Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
300765 CSPC Innovation Pharmaceutical
- 26.79
- -0.56-2.05%
Market Closed Dec 20 15:00 CST
37.63BMarket Cap73.40P/E (TTM)
27.47High26.60Low88.77KlotVolume27.42Open27.35Pre Close238.44MTurnover0.71%Turnover Ratio49.80P/E (Static)1.40BShares37.0852wk High9.87P/B33.41BFloat Cap19.4352wk Low32.82Limit Up1.25BShs Float40.36Historical High21.88Limit Down3.18%Amplitude4.52Historical Low0.27Dividend TTM26.86Avg Price53.64KlotAsk1.00%Div YieldTTM100Lot Size32.07KlotBid
CSPC Innovation Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -23.66%1.48B | -27.71%971.86M | -27.08%524.07M | -4.75%2.5B | 2.33%1.94B | 8.26%1.34B | 32.84%718.72M | 42.00%2.63B | 80.54%1.89B | 75.53%1.24B |
| Operating revenue | -23.66%1.48B | -27.71%971.86M | -27.08%524.07M | -4.75%2.5B | 2.33%1.94B | 8.26%1.34B | 32.84%718.72M | 42.00%2.63B | 80.54%1.89B | 75.53%1.24B |
| Other operating revenue | ---- | 16.08%28.68M | ---- | -7.05%51.35M | ---- | -22.13%24.71M | ---- | -8.14%55.25M | ---- | 20.31%31.73M |
| Total operating cost | -12.23%1.46B | -21.51%904.05M | -24.61%459.22M | -7.92%1.64B | 29.84%1.66B | 36.61%1.15B | 57.71%609.16M | 28.31%1.79B | 68.49%1.28B | 64.30%843.13M |
| Operating cost | -16.79%843.1M | -22.71%546.32M | -23.96%279.3M | -8.31%1.37B | -5.77%1.01B | 0.72%706.85M | 23.21%367.33M | 43.25%1.49B | 108.58%1.08B | 109.63%701.82M |
| Operating tax surcharges | -13.62%24.49M | -8.71%16.88M | -5.03%8.85M | 40.05%28.75M | 97.65%28.35M | 106.28%18.49M | 163.71%9.32M | 29.92%20.53M | 47.30%14.35M | 20.70%8.96M |
| Operating expense | -38.97%107.92M | -35.68%73.26M | -21.44%53.04M | -15.97%205.23M | -4.68%176.83M | -6.69%113.91M | -1.97%67.51M | -8.11%244.25M | -13.22%185.5M | -20.97%122.08M |
| Administration expense | -5.69%57.26M | 0.16%43.08M | 30.91%23.71M | 24.54%86.57M | 30.41%60.71M | 57.31%43.01M | 46.73%18.11M | 16.92%69.52M | 60.91%46.56M | 31.95%27.34M |
| Financial expense | 43.35%-29.36M | 9.32%-27.35M | -356.32%-16.15M | -4.61%-90.78M | 23.59%-51.83M | 2.33%-30.16M | 251.75%6.3M | -401.59%-86.78M | -251.52%-67.84M | -169.47%-30.88M |
| -Interest expense (Financial expense) | -81.79%2.88M | -78.14%2.86M | -91.92%17.71K | 62.19%355.57K | 2,118.56%15.79M | 2,036.96%13.09M | 2,297.12%219.23K | -92.26%219.23K | --711.71K | 1,720.60%612.69K |
| -Interest Income (Financial expense) | 28.80%-33.48M | 15.27%-24.74M | 56.61%-14.21M | -101.24%-65.9M | -135.08%-47.02M | -111.21%-29.19M | -369.57%-32.75M | -18.40%-32.75M | 2.72%-20M | -20.57%-13.82M |
| Research and development | 4.67%456.96M | -15.97%251.86M | -21.42%110.48M | 0.52%46.54M | 1,479.81%436.56M | 2,069.64%299.71M | 1,767.95%140.59M | 74.71%46.3M | 132.06%27.63M | 91.76%13.81M |
| Credit Impairment Loss | -238.69%-3.49M | -462.24%-1.78M | -1,424.00%-5.22M | 162.20%4.86M | 132.78%2.51M | 108.02%491.7K | 87.47%-342.21K | -30.32%-7.82M | -136.25%-7.67M | -74.45%-6.13M |
| Asset Impairment Loss | ---625K | ---625K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other net revenue | -92.18%949.31K | -110.62%-818.34K | -620.97%-8.69M | 132.15%33.62M | 653.61%12.15M | 594.61%7.7M | 265.94%1.67M | -50.38%14.48M | -85.87%1.61M | -120.66%-1.56M |
| Fair value change income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -41.39%1.28M | -66.56%778.14K |
| Invest income | -257.12%-2.85M | -500.40%-3.79M | -554.56%-4.61M | -25.21%12.58M | -64.97%1.81M | -52.01%947.48K | -151.09%-704.63K | -5.05%16.82M | -33.50%5.17M | -65.15%1.97M |
| -Including: Investment income associates | -257.12%-2.85M | -500.40%-3.79M | ---- | 22.10%12.58M | 117.17%1.81M | 737.19%947.48K | ---- | 40.92%10.3M | 346.26%834.49K | -179.64%-148.7K |
| Asset deal income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --117.54K | ---- | ---- |
| Other revenue | 1.14%7.91M | -14.09%5.38M | -58.09%1.14M | 201.67%16.18M | 176.78%7.82M | 243.96%6.26M | 681.64%2.71M | -70.57%5.36M | -39.69%2.83M | -40.51%1.82M |
| Operating profit | -93.17%19.51M | -66.54%67M | -49.51%56.16M | 4.18%891.35M | -53.44%285.57M | -49.57%200.21M | -27.67%111.22M | 75.55%855.59M | 104.80%613.35M | 96.74%397.04M |
| Add:Non operating Income | -77.40%1.48M | -73.34%934.58K | -12.79%657.86K | 16.04%2.89M | -2.51%6.54M | 62.25%3.51M | 21.53%754.32K | 183.72%2.49M | 614.34%6.71M | 562.54%2.16M |
| Less:Non operating expense | -16.72%1.86M | 239.52%915.13K | --29.32K | -63.44%2.45M | -63.26%2.24M | -95.14%269.53K | ---- | -34.56%6.71M | 255.14%6.09M | 246.11%5.55M |
| Total profit | -93.40%19.12M | -67.06%67.02M | -49.29%56.78M | 4.75%891.79M | -52.79%289.88M | -48.32%203.45M | -25.70%111.98M | 78.11%851.37M | 105.54%613.97M | 96.31%393.65M |
| Less:Income tax cost | -35.62%65.61M | -43.85%38.62M | -19.53%26.82M | 9.39%136.47M | 6.01%101.9M | 11.64%68.77M | 22.46%33.33M | 46.28%124.76M | 76.56%96.13M | 64.90%61.6M |
| Net profit | -124.73%-46.48M | -78.91%28.4M | -61.90%29.96M | 3.95%755.32M | -63.70%187.97M | -59.44%134.68M | -36.32%78.65M | 85.03%726.61M | 112.00%517.85M | 103.50%332.05M |
| Net profit from continuing operation | -124.73%-46.48M | -78.91%28.4M | -61.90%29.96M | 3.95%755.32M | --187.97M | -59.44%134.68M | -36.32%78.65M | 85.03%726.61M | ---- | 103.50%332.05M |
| Less:Minority Profit | 4.11%-185.81M | 16.58%-108.63M | 3.07%-49.1M | -171.81%-239.7K | -60,544.35%-193.78M | -64,950.89%-130.22M | -286,426.55%-50.66M | 163.23%333.78K | 277.06%320.6K | 167.36%200.8K |
| Net profit of parent company owners | -63.50%139.33M | -48.27%137.03M | -38.86%79.06M | 4.03%755.56M | -26.23%381.76M | -20.18%264.9M | 4.68%129.3M | 84.70%726.28M | 111.71%517.53M | 103.00%331.85M |
| Earning per share | ||||||||||
| Basic earning per share | -63.66%0.0995 | -47.37%0.1 | -40.44%0.0676 | 0.21%0.6533 | -48.01%0.2738 | -43.74%0.19 | -43.11%0.1135 | 2.61%0.6519 | 17.62%0.5266 | 12.94%0.3377 |
| Diluted earning per share | -63.66%0.0995 | -47.37%0.1 | -40.44%0.0676 | 0.21%0.6533 | -48.01%0.2738 | -43.74%0.19 | -43.11%0.1135 | 2.61%0.6519 | 17.62%0.5266 | 12.94%0.3377 |
| Other composite income | -151.38%-502.39K | -122.58%-382.21K | -212.69%-372.43K | -34.15%1.27M | 186.59%977.86K | 277.73%1.69M | -134.91%-119.11K | 273.95%1.92M | 173.78%341.2K | 222.88%448.1K |
| Other composite income of parent company owners | -151.38%-502.39K | -122.58%-382.21K | -212.69%-372.43K | -34.15%1.27M | 186.59%977.86K | 277.73%1.69M | -134.91%-119.11K | 273.95%1.92M | 173.78%341.2K | 222.88%448.1K |
| Total composite income | -124.87%-46.98M | -79.46%28.02M | -62.32%29.59M | 3.85%756.58M | -63.54%188.95M | -58.99%136.37M | -36.59%78.53M | 86.04%728.53M | 112.54%518.19M | 104.23%332.5M |
| Total composite income of parent company owners | -63.73%138.83M | -48.74%136.65M | -39.09%78.69M | 3.93%756.82M | -26.09%382.73M | -19.77%266.59M | 4.30%129.18M | 85.71%728.2M | 112.25%517.87M | 103.73%332.3M |
| Total composite income of minority owners | 4.11%-185.81M | 16.58%-108.63M | 3.07%-49.1M | -171.81%-239.7K | -60,544.35%-193.78M | -64,950.89%-130.22M | -286,426.55%-50.66M | 163.23%333.78K | 277.06%320.6K | 167.36%200.8K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
